GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan
· Delayed Price · Currency is TWD 19.30
-0.40 (-2.03%)
Apr 29, 2026, 1:30 PM CST
GeneReach Biotechnology Revenue
In the year 2025, GeneReach Biotechnology had annual revenue of 232.74M TWD with 12.71% growth. GeneReach Biotechnology had revenue of 72.38M in the quarter ending December 31, 2025, with 31.69% growth.
Revenue
232.74M
Revenue Growth
+12.71%
P/S Ratio
4.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 232.74M | 26.25M | 12.71% |
| Dec 31, 2024 | 206.49M | -18.97M | -8.41% |
| Dec 31, 2023 | 225.46M | -524.56M | -69.94% |
| Dec 31, 2022 | 750.02M | -262.06M | -25.89% |
| Dec 31, 2021 | 1.01B | 155.04M | 18.09% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Holy Stone Healthcare | 47.51M |
| Level Biotechnology | 736.59M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| Lukas Biomedical | 180.32M |
| TCI GENE | 273.61M |
| Abnova (Taiwan) | 351.30M |
| Meribank Biotech | 471.76M |
| Enimmune | 48.19M |